JNP Medi (CEO Jeong Gwon-ho) , a consulting firm specializing in the development of new drugs and innovative medical devices based on an AI platform, announced that it has been selected as a second round of startups for the "2025 Global TIPS Commercialization Program," hosted by the Ministry of SMEs and Startups. With this selection, JNP Medi will begin its full-scale expansion into the Asia-Pacific (APAC) market.
Global TIPS is a government program that provides commercialization funding and global expansion programs to promising startups that have attracted at least $300,000 in investment from overseas venture capital (VC) firms. J&P Medi's selection recognizes the technological competitiveness and global expansion potential of its AI-based clinical trial data platform.
J&P Medi is expanding its business in the APAC region, focusing on its core solution, "Maven Clinical Cloud." This platform is a B2B SaaS-based clinical trial data management solution that leverages AI, cloud, and blockchain technologies. It integrates electronic case record forms (eCRFs), electronic protocols (eProtocols), and electronic consent forms (eConsents), digitizing the entire clinical trial process.
This automates the data entry and review process, reducing the workload on researchers while enhancing data quality and reliability, improving the overall efficiency of clinical trials. Furthermore, the goal is to reduce the time and costs required to develop new drugs and innovative medical devices.
The APAC region is recognized for its strengths in cost-effectiveness, rapid patient recruitment, and ethnic diversity, and is attracting attention as a key clinical trial hub for global pharmaceutical and bio companies. Leveraging these market characteristics, J&P Medi plans to continuously strengthen its digital transformation competitiveness in platform-based clinical trials.
Jeong Gwon-ho, CEO of JNP Medi, said, “With this selection as a Global TIPS, we will further enhance the technological perfection and scalability of Maven Clinical Cloud and continue to expand the use of digital technologies in global clinical trial environments, including APAC.”
- See more related articles
You must be logged in to post a comment.